Akorn (NASDAQ:AKRX) has been under a strong bear grip, hence the stock is down -0.25% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 2.62% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.93% in the last 1 week, and is up 1.36% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -29.74% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $47.35 and the one year low was seen on Mar 18, 2016. The 50-Day Moving Average price is $29.79 and the 200 Day Moving Average price is recorded at $27.63.
The stock has recorded a 20-day Moving Average of 5.27% and the 50-Day Moving Average is 7.38%.
Akorn (NASDAQ:AKRX): stock turned positive on Friday. Though the stock opened at $29.99, the bulls momentum made the stock top out at $31.02 level for the day. The stock recorded a low of $29.9632 and closed the trading day at $30.66, in the green by 2.13%. The total traded volume for the day was 1,883,025. The stock had closed at $30.02 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Bonaccorsi Joseph, officer (Sr VP Gen Counsel & Secretary) of Akorn Inc, had unloaded 6,500 shares at an average price of $29.84 in a transaction dated on June 14, 2016. The total value of the transaction was worth $193,960.
Akorn Inc. (Akorn), together with its wholly owned subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as animal and over-the-counter (OTC) consumer health products. The Company specializes in sterile and non-sterile dosage forms, including ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company operates in two segments: Prescription Pharmaceuticals, which is engaged in the sale of branded and generic prescription pharmaceuticals, and Consumer Health, which is engaged in the sale of branded and private label consumer and animal health products. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York, and Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, and an additional warehousing facility in Amityville, New York.